Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.59 |
| ▸ | PDE4A | P27815 | 3/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | BRD2 | P25440 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13343375 | 0.95 | ADORA2A (0.55) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13368751 | 0.94 | ADORA2A (0.53) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7419694 | 0.85 | PDE4A (0.47) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10963141 | 0.84 | ADORA2A (0.55) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4626790 | 0.84 | ADORA2A (0.58) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3178085 | 0.84 | ADORA2A (0.58) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10873660 | 0.83 | ADORA2A (0.46) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7621617 | 0.83 | ADORA2A (0.54) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3848060 | 0.82 | ADORA2A (0.57) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13368841 | 0.82 | PDE2A (0.47) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875126-B1 | ERYTHROID PRODUCTION | THE COMMON SERVICES AGENCY (GB) | 2018-01-17 | — | — | EP | claimed |
| US-20150203818-A1 | ERYTHROID PRODUCTION | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2015-07-23 | — | — | US | claimed |
| EP-2875126-A1 | ERYTHROID PRODUCTION | The Common Services Agency (GB) | 2015-05-27 | — | — | EP | claimed |
| WO-2014013255-A1 | ERYTHROID PRODUCTION | THE COMMON SERVICES AGENCY (GB) | 2014-01-23 | — | — | WO | claimed |
| WO-2009131948-A2 | HIGH-THROUGHPUT CELL-BASED CFTR ASSAY | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| EP-0956855-B1 | Immunosuppressive effects of 8 substituted xanthine derivatives | LEUVEN K U RES & DEV (BE) | 2003-03-12 | — | — | EP | claimed |
| EP-0956855-A1 | Immunosuppressive effects of 8-substituted xanthine derivatives | K.U. Leuven Research & Development (BE) | 1999-11-17 | — | — | EP | claimed |
| US-20250283041-A1 | METHODS FOR PRODUCING RED BLOOD CELLS | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4532693-A1 | METHODS FOR PRODUCING RED BLOOD CELLS | Albert Einstein College of Medicine (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023230405-A1 | METHODS FOR PRODUCING RED BLOOD CELLS | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-2875126-B1 | ERYTHROID PRODUCTION | THE COMMON SERVICES AGENCY (GB) | 2018-01-17 | — | — | EP | disclosed |
| EP-3247790-A1 | CELL MATURATION PROCESS | Scottish National Blood Transfusion Service (GB) | 2017-11-29 | — | — | EP | disclosed |
| CN-107029209-A | Guanylate cyclase receptor activator for treating tissue inflammation and canceration | 药物协和公司 | 2017-08-11 | — | — | CN | disclosed |
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | disclosed |
| EP-0535038-A4 | MAMMALIAN ADIPOGENIC FACTORS | — | 1993-12-29 | — | — | EP | disclosed |
| EP-0535038-A1 | MAMMALIAN ADIPOGENIC FACTORS | W. ALTON JONES CELL SCIENCE CENTER (US) | 1993-04-07 | — | — | EP | disclosed |
| WO-1991018924-A1 | MAMMALIAN ADIPOGENIC FACTORS | W. ALTON JONES CELL SCIENCE CENTER (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0308460-A1 | A COMPOSITION FOR THE TOPICAL TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION. | PHARMACIA AB (SE) | 1989-03-29 | — | — | EP | disclosed |
| WO-1988007380-A1 | A COMPOSITION FOR THE TOPICAL TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | PHARMACIA AB (SE) | 1988-10-06 | — | — | WO | disclosed |
| EP-0039780-A1 | Di- or trisubstituted xanthines with neuroleptic activity, process for their preparation and pharmaceutical preparations containing them | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1981-11-18 | — | — | EP | disclosed |